Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (191-200 of 578) with videos related to

Pageof 58
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 8, 2011
Evolution in endometrial cancer: evidence from an immunohistochemical studyIngrid Vandenput, Jone Trovik, Karin Leunen, et al.
Journal of Medical Case Reports|August 6, 2010
High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case reportFrédéric Amant, Kristel Van Calsteren, Maria Debiec-Rychter, et al.
British Journal of Cancer|April 4, 2026
Value of whole-body diffusion-weighted MRI for the prediction of surgical and clinical outcome after neoadjuvant chemotherapy in advanced ovarian cancerVincent Vandecaveye, Raphaëla C Dresen, Thaïs Baert, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|December 18, 2008
Feasibility of ultrasound-guided percutaneous samplings in the pregnant baboon: a model for studies on transplacental transportKristel Van Calsteren, Roland Devlieger, Luc De Catte, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 30, 2016
mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70)An Coosemans, Sandra Tuyaerts, Kim Morias, et al.
Gynecologic Oncology|May 13, 2018
Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patientsThaïs Baert, Joke Van Camp, Lisa Vanbrabant, et al.
Breast Cancer Research and Treatment|April 14, 2007
Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?Karin Leunen, Maria Drijkoningen, Patrick Neven, et al.
Gynecologic Oncology|December 25, 2019
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancerRebecca C Arend, Allison M Davis, Przemyslaw Chimiczewski, et al.
Anticancer Research|September 12, 2013
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcomaAn Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, et al.
Oncology Reports|December 13, 2012
Increased expression of placental growth factor in high-grade endometrial carcinomaLieve Coenegrachts, Stefanie Schrauwen, Rita Van Bree, et al.
Pageof 58

Showing results (191-200 of 578) with videos related to

Sort By:
Pageof 58
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 8, 2011
Evolution in endometrial cancer: evidence from an immunohistochemical studyIngrid Vandenput, Jone Trovik, Karin Leunen, et al.
Journal of Medical Case Reports|August 6, 2010
High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case reportFrédéric Amant, Kristel Van Calsteren, Maria Debiec-Rychter, et al.
British Journal of Cancer|April 4, 2026
Value of whole-body diffusion-weighted MRI for the prediction of surgical and clinical outcome after neoadjuvant chemotherapy in advanced ovarian cancerVincent Vandecaveye, Raphaëla C Dresen, Thaïs Baert, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|December 18, 2008
Feasibility of ultrasound-guided percutaneous samplings in the pregnant baboon: a model for studies on transplacental transportKristel Van Calsteren, Roland Devlieger, Luc De Catte, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 30, 2016
mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70)An Coosemans, Sandra Tuyaerts, Kim Morias, et al.
Gynecologic Oncology|May 13, 2018
Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patientsThaïs Baert, Joke Van Camp, Lisa Vanbrabant, et al.
Breast Cancer Research and Treatment|April 14, 2007
Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?Karin Leunen, Maria Drijkoningen, Patrick Neven, et al.
Gynecologic Oncology|December 25, 2019
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancerRebecca C Arend, Allison M Davis, Przemyslaw Chimiczewski, et al.
Anticancer Research|September 12, 2013
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcomaAn Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, et al.
Oncology Reports|December 13, 2012
Increased expression of placental growth factor in high-grade endometrial carcinomaLieve Coenegrachts, Stefanie Schrauwen, Rita Van Bree, et al.
Pageof 58